MTAP and pancreatic ductal adenocarcinoma: Other studies had reported MTAP deficiency by IHC in 27–30% [22,23,24] and deep deletions by next-generation sequencing (NGS) in 2–21% of ductal adenocarcinomas of the pancreas [25,26].